CN108366998A - 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 - Google Patents

在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 Download PDF

Info

Publication number
CN108366998A
CN108366998A CN201680071092.XA CN201680071092A CN108366998A CN 108366998 A CN108366998 A CN 108366998A CN 201680071092 A CN201680071092 A CN 201680071092A CN 108366998 A CN108366998 A CN 108366998A
Authority
CN
China
Prior art keywords
patient
cancer
bases
pik3ca
pi3k inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680071092.XA
Other languages
English (en)
Chinese (zh)
Inventor
托玛索 E·迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN108366998A publication Critical patent/CN108366998A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680071092.XA 2015-12-03 2016-11-30 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症 Pending CN108366998A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262620P 2015-12-03 2015-12-03
US62/262,620 2015-12-03
PCT/IB2016/057208 WO2017093905A1 (en) 2015-12-03 2016-11-30 Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna

Publications (1)

Publication Number Publication Date
CN108366998A true CN108366998A (zh) 2018-08-03

Family

ID=57517943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680071092.XA Pending CN108366998A (zh) 2015-12-03 2016-11-30 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症

Country Status (13)

Country Link
US (2) US20180353515A1 (cg-RX-API-DMAC7.html)
EP (1) EP3383391A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018535997A (cg-RX-API-DMAC7.html)
KR (1) KR20180084830A (cg-RX-API-DMAC7.html)
CN (1) CN108366998A (cg-RX-API-DMAC7.html)
AU (1) AU2016362683B2 (cg-RX-API-DMAC7.html)
CA (1) CA3006419A1 (cg-RX-API-DMAC7.html)
HK (1) HK1253737A1 (cg-RX-API-DMAC7.html)
IL (1) IL259716A (cg-RX-API-DMAC7.html)
MX (1) MX2018006777A (cg-RX-API-DMAC7.html)
RU (1) RU2018123524A (cg-RX-API-DMAC7.html)
TW (1) TW201722429A (cg-RX-API-DMAC7.html)
WO (1) WO2017093905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210355545A1 (en) * 2018-10-15 2021-11-18 The Johns Hopkins University Methods and materials for assessing and treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271136A (zh) * 2012-03-29 2015-01-07 诺华股份有限公司 药学诊断
WO2015172085A2 (en) * 2014-05-09 2015-11-12 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1641809B2 (en) 2003-07-05 2018-10-03 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
PT3296407T (pt) 2004-03-02 2019-08-23 Univ Johns Hopkins Mutações do gene pik3ca em cancros humanos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP5658565B2 (ja) 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20130317037A1 (en) * 2010-11-16 2013-11-28 Glaxosmithkline Intellectual Property Development Limited Method of administration and treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271136A (zh) * 2012-03-29 2015-01-07 诺华股份有限公司 药学诊断
WO2015172085A2 (en) * 2014-05-09 2015-11-12 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRITSCH, C.ET AL: ""Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials"", 《MOLECULAR CANCER THERAPEUTICS》 *
MASSACESI, C. ET AL: ""Overcoming Phosphatidylinositol 3-Kinase (PI3K) Activation in Breast Cancer: Emerging PI3K Inhibitors"", 《THE JOURNAL OF ONCOPATHOLOGY》 *
OSHIRO, C. ET AL: ""PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients"", 《BREAST CANCER RESEARCH AND TREATMENT》 *
PAYAL D. SHAH ET AL: ""Abstract PD5-3: Phase I trial: P13K[aIpha] inhibitor BY L719 plus aromatase inhibitor (Al) for patients with hormone receptorpositive (HR+) metastatic breast cancer (MBC)"", 《CANCER RESEARCH》 *

Also Published As

Publication number Publication date
WO2017093905A1 (en) 2017-06-08
CA3006419A1 (en) 2017-06-08
IL259716A (en) 2018-07-31
AU2016362683A1 (en) 2018-05-31
AU2016362683B2 (en) 2019-11-07
TW201722429A (zh) 2017-07-01
EP3383391A1 (en) 2018-10-10
US20200138824A1 (en) 2020-05-07
HK1253737A1 (zh) 2019-06-28
RU2018123524A (ru) 2020-01-09
MX2018006777A (es) 2018-08-01
US20180353515A1 (en) 2018-12-13
KR20180084830A (ko) 2018-07-25
JP2018535997A (ja) 2018-12-06
RU2018123524A3 (cg-RX-API-DMAC7.html) 2020-04-02

Similar Documents

Publication Publication Date Title
JP7323393B2 (ja) ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
He et al. The G protein α subunit Gα s is a tumor suppressor in Sonic hedgehog− driven medulloblastoma
Idzko et al. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release
Küsters‐Vandevelde et al. Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects
Domínguez-Soto et al. Serotonin drives the acquisition of a profibrotic and anti-inflammatory gene profile through the 5-HT7R-PKA signaling axis
RU2602185C2 (ru) Биомаркеры для терапии на основе ингибитора hedgehog
JP2013528228A (ja) キナゾリノン化合物による選択した患者における血液系障害を処置する方法
US11685953B2 (en) Biomarkers and methods of treating cancer
McCulley et al. PBX transcription factors drive pulmonary vascular adaptation to birth
RU2663701C2 (ru) Маркеры, ассоциированные с ингибиторами wnt
US20140148483A1 (en) Method For Predicting Effectiveness Of Angiogenesis Inhibitor
JP2018531223A6 (ja) 癌を治療するための新規のバイオマーカーおよび方法
Wang et al. Studying the mechanism of sperm DNA damage caused by folate deficiency
CA3200256A1 (en) Methods and systems of stratifying inflammatory disease patients
ES2873926T3 (es) Método para predecir una respuesta al tratamiento con un antagonista del receptor V1B en un paciente con síntomas depresivos y/o síntomas de ansiedad
da Cunha Vasconcelos et al. Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice
CN113645991A (zh) 靶向il18r1的、用于治疗炎性疾病的方法、系统和试剂盒
JP2023500950A (ja) マントル細胞リンパ腫（ｍｃｌ）対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法
JP5876827B2 (ja) 癌を治療する方法
CN108366998A (zh) 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症
WO2015066432A1 (en) Method of treating post-myeloproliferative neoplasms (mpns) and post-mpn acute myeloid leukemia
KR20230087445A (ko) Aml의 치료 요법 및 rara 작용제, 저메틸화제, 및 bcl-2 억제제의 용도
JP2022500020A (ja) リンパ系疾患の診断および治療のための組成物および方法
WO2015066439A2 (en) Methods of treating hematological malignancies
US20250334588A1 (en) Treating tuberous sclerosis complex-associated diseases

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180803

WD01 Invention patent application deemed withdrawn after publication